Government Proposal to Legalize E-cigarette Sales Sparks Medical Concern

Aug.20.2024
Government Proposal to Legalize E-cigarette Sales Sparks Medical Concern
Brazilian senator Soraya Thronicke's proposal to legalize e-cigarette sales will be debated in the Senate, sparking medical entities' opposition.

According to Tnonline on August 19th, Brazilian Senator Soraya Thronicke proposed a bill to allow for the commercial sale of e-cigarettes. After multiple delays, the bill is now on the agenda for the Senate's Economic Affairs Committee (CAE) on August 20th, sparking concern from 80 medical entities opposed to the proposal.


In a statement led by the Brazilian Medical Association (AMB) and the Brazilian Society of Pulmonology and Tuberculosis (SBPT), these organizations strongly reaffirmed their opposition to changes in e-cigarette regulation.


Dr. Ricardo Meirelles, coordinator of the AMB Smoking Control Committee, stated that,...


This proposal is irresponsible towards the Brazilian people, as it aims to open up the sale of a harmful product to public health.


In April of this year, Anvisa unanimously decided to continue to ban the manufacturing, importation, and sale of e-cigarette products in Brazil. However, if the bill is approved in the Senate, it will be directly sent to the House of Representatives for review without requiring Anvisa's approval.


Soraya's proposal argues that the initial ban was based on a principle of public health supervision - the precautionary principle - because at that time there was little understanding of these products. Since then, despite not being approved, the use of e-cigarettes has increased, preventing sales is like "closing one's eyes to reality". In her proposal written in 2023, she emphasizes that.


The ban failed to address the issue, strict sales rules need to be established.


She compared Anvisa's resolution with the approval of the US FDA.


If the proposal is passed, e-cigarettes will be taxed. According to lawmakers in support of the proposal, it is estimated that the tax revenue could reach 22 billion Brazilian Reais (4.06 billion US dollars) annually. However, the medical community argues that this amount is not enough to cover the medical expenses resulting from an increase in respiratory diseases. In 2022 alone, Brazil has already spent 153.5 billion Reais (283.8 billion US dollars) on healthcare costs and lost productivity caused by tobacco use.


Paulo César Rodrigues Pinto Correa, coordinator of the SBPT Research Committee, highlighted the political manipulation surrounding the issue of e-cigarettes and emphasized the need for increased regulation and measures to combat illegal sales. Otherwise, the increase in illegal sales will continue to be used as an excuse to support attempts to lift the ban.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

FDA nicotine pouch review delay report knocks tobacco shares lower
FDA nicotine pouch review delay report knocks tobacco shares lower
After Reuters reported before the market open that FDA reviews of nicotine pouch applications could face delays, shares of Philip Morris International, Turning Point Brands and British American Tobacco fell on April 1, underscoring the direct impact of U.S. regulatory signals on major tobacco companies and nicotine pouch expectations.
Apr.02
Al Fakher Enters the Oral Nicotine Market With Four Flavors
Al Fakher Enters the Oral Nicotine Market With Four Flavors
Al Fakher has launched nicotine pouches, marking the world’s leading hookah brand’s entry into the modern oral nicotine category.
Apr.01 by 2FIRSTS.ai
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
U.S. Food and Drug Administration’s Center for Tobacco Products held a formal listening session with IKE Tech LLC to discuss youth prevention at the point of use for ENDS products, the circulation of illicit products in the supply chain, and the regulatory treatment of software in tobacco products.
Apr.10 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan Unveils TEREA “Blossom Pearl” for IQOS ILUMA
Philip Morris Japan announced that it will launch “TEREA Blossom Pearl,” a new tobacco stick for IQOS ILUMA, on May 11. The new product will expand the TEREA lineup to 27 variants. It features a capsule menthol flavor with strawberry and subtle herbal notes and is priced at JPY 620, or about USD 4.14 based on an assumed rate of 1 JPY = 0.00668 USD. The exchange-rate source should be verified and added.
Apr.28 by 2FIRSTS.ai
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Breaking: Smoore Shares Fall More Than 16% Intraday in Morning Trade After Results Release, Investor Presentation
Smoore International (6969.HK) released its 2025 results on March 17 and held an investor presentation on the morning of March 18. In morning trade on March 18, the company’s shares fell more than 16% intraday, hitting a low of HK$9.94.
Mar.18 by 2FIRSTS.ai